Author

Rachel O. Abelman

Harvard UniversityORCID 0000-0002-3946-7420Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Assay:imaging· 1 Assay:spatial transcriptomics· 1

Frequent Co-Authors

Aditya BardiaiD· 2 shared David Tsai TingiD· 2 shared Katherine H. XuiD· 2 shared Leif William ElliseniD· 2 shared Linda T. NiemaniD· 2 shared Akansha Deshpande· 1 shared Avanish MishraiD· 1 shared Bidish K. PateliD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Aditya BardiaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyProceedings of the National Academy of SciencesPeer-reviewedJun 17, 2026

✦ In-depth digest

Dynamic Monitoring of Antibody Drug Conjugates Targeting TROP2 or HER2 in Breast Cancer using Circulating Tumor Cells

Avanish Mishra, Rachel O. Abelman, Quinn E. Cunneely…·Shyamala Maheswaran

In metastatic breast cancer on TROP2- or HER2-targeting antibody-drug conjugates, early CTC disappearance or steep decline tracked response, while CTC epitope levels neither predicted benefit nor vanished at resistance.

9 citationstop 1%

humanimaging

𝕏 PostBluesky

Cancer BiologyJournal for ImmunoTherapy of CancerPeer-reviewedApr 1, 2026

A TROP2/Claudin Program Mediates Immune Exclusion to Impede Checkpoint Blockade in Breast Cancer

Bogang Wu, Win Thant, Elena Bitman…·Leif William Ellisen

This study identifies TROP2 as a regulator of tight junction-mediated immune exclusion in TNBC, showing that targeting TROP2 enhances anti-PD1 therapy response.

11 citationstop 1%

humanspatial transcriptomics

𝕏 PostBluesky